|
DE69720965T2
(de)
|
1996-02-13 |
2004-02-05 |
Astrazeneca Ab |
Chinazolinderivate und deren verwendung als vegf hemmer
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
AU5003200A
(en)
|
1999-05-14 |
2000-12-05 |
United States Of America As Represented By The Department Of Veterans Affairs, The |
Isolation and characterization of epidermal growth factor related protein
|
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
|
KR100881105B1
(ko)
*
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
|
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
ES2267748T3
(es)
|
2000-04-07 |
2007-03-16 |
Astrazeneca Ab |
Compuestos de quinazolina.
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
WO2002016352A1
(en)
|
2000-08-21 |
2002-02-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
AU2001292137A1
(en)
*
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
HUP0500200A2
(hu)
*
|
2002-01-17 |
2005-07-28 |
Neurogen Corporation |
Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
EP1569925A1
(en)
*
|
2002-12-13 |
2005-09-07 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
ATE395346T1
(de)
|
2003-09-16 |
2008-05-15 |
Astrazeneca Ab |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
KR20080095915A
(ko)
|
2004-05-06 |
2008-10-29 |
워너-램버트 캄파니 엘엘씨 |
4-페닐아미노-퀴나졸린-6-일-아미드
|
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
|
ATE488513T1
(de)
|
2005-09-20 |
2010-12-15 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
|
US8497369B2
(en)
|
2008-02-07 |
2013-07-30 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
|
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
|
|
EP2313397B1
(de)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
EP2349235A1
(en)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
|
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2408479A1
(en)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
CA2780875A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
EP2751285B2
(en)
|
2011-08-31 |
2020-04-01 |
Genentech, Inc. |
Method for sensitivity testing of a tumour for a egfr kinase inhibitor
|
|
EP2761025A1
(en)
|
2011-09-30 |
2014-08-06 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
US9834575B2
(en)
|
2013-02-26 |
2017-12-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2016105503A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
CN110366550A
(zh)
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
|
AU2018273356B2
(en)
|
2017-05-22 |
2021-09-16 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
EP3788053B1
(en)
|
2018-05-04 |
2024-07-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
|
CN113194954A
(zh)
|
2018-10-04 |
2021-07-30 |
国家医疗保健研究所 |
用于治疗角皮病的egfr抑制剂
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
AU2019384118B2
(en)
|
2018-11-19 |
2025-06-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
JP2022513967A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
|
|
JP7686559B2
(ja)
|
2018-12-20 |
2025-06-02 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤
|
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
|
AU2019401495B2
(en)
|
2018-12-20 |
2025-06-26 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
|
MX2021010323A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos bicíclicos de heterociclilo y usos de este.
|
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
EP4007753B1
(en)
|
2019-08-02 |
2025-09-24 |
Amgen Inc. |
Kif18a inhibitors
|
|
EP4007638A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
|
EP4007756B1
(en)
|
2019-08-02 |
2025-12-24 |
Amgen Inc. |
Kif18a inhibitors
|
|
EP4007752B1
(en)
|
2019-08-02 |
2025-09-24 |
Amgen Inc. |
Kif18a inhibitors
|
|
EP4048671B1
(en)
|
2019-10-24 |
2026-03-18 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CA3156359A1
(en)
|
2019-11-08 |
2021-05-14 |
Adrian Liam Gill |
Bicyclic heteroaryl compounds and uses thereof
|
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
|
|
JP7837865B2
(ja)
|
2019-11-14 |
2026-03-31 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改良合成法
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021142026A1
(en)
|
2020-01-07 |
2021-07-15 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
US20250195521A1
(en)
|
2020-09-03 |
2025-06-19 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP7849366B2
(ja)
|
2020-12-22 |
2026-04-21 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Ｓｏｓ１阻害剤およびその使用
|
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ｒａｓ阻害剤及びその使用
|
|
TW202309052A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
CN119212994A
(zh)
|
2021-12-17 |
2024-12-27 |
建新公司 |
作为shp2抑制剂的吡唑并吡嗪化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
KR20240156373A
(ko)
|
2022-03-07 |
2024-10-29 |
암젠 인크 |
4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2023358792A1
(en)
|
2022-10-14 |
2025-04-17 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202542151A
(zh)
|
2023-12-22 |
2025-11-01 |
美商銳格醫藥有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|